Bristol Myers (BMY) will spend $40B in the U.S. over the next five years, CEO Christopher Boerner wrote in STAT. Through this investment plan, “we will strengthen our presence across the country, ramp up radiopharmaceutical manufacturing, and invest in artificial intelligence and machine learning to help us significantly increase the pace of innovation,” Boerner said. “It is our commitment to patients that drives each investment we make.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers appoints Cari Gallman as Chief Policy Officer
- Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says
- Trump urges drugmakers to accept lower prices on prescriptions, Bloomberg says
- Insider Moves: Procter & Gamble, Strategy, Merck, Bristol-Myers, AGNC
- MHRA authorizes under-skin injection version of Bristol Myers’ Opdivo